Patents by Inventor Joseph Belanoff
Joseph Belanoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240100052Abstract: Applicant discloses methods and compositions for reducing liver fat and for treating fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH) and nonalcoholic cirrhosis; alcohol related fatty liver diseases including, alcohol fatty liver disease (AFL), alcoholic steatohepatitis (ASH), and alcoholic cirrhosis; and liver fibrosis). Significant liver fat reductions were obtained in human patients after only between 30 to 44 days of administration of 600 mg/day or 900 mg/day of the cyclohexyl pyrimidine glucocorticoid receptor modulator miricorilant. Liver fat reductions ranged from 38.5% to 73.8% (magnetic resonance imaging measurements in 4 of 5 patients receiving miricorilant, measured between 16-64 days after cessation of miricorilant administration). A further effect of miricorilant was an increase in liver alanine amino transferase (ALT) and aspartate amino transferase (AST).Type: ApplicationFiled: November 22, 2023Publication date: March 28, 2024Applicant: Corcept Therapeutics IncorporatedInventors: Ada Lee, Andreas Grauer, Joseph Belanoff
-
Publication number: 20240075030Abstract: Applicant discloses methods and compositions for reducing liver fat and for treating fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH) and nonalcoholic cirrhosis; alcohol related fatty liver diseases including, alcohol fatty liver disease (AFL), alcoholic steatohepatitis (ASH), and alcoholic cirrhosis; and liver fibrosis). Significant liver fat reductions were obtained in human patients after only between 30 to 44 days of administration of 600 mg/day or 900 mg/day of the cyclohexyl pyrimidine glucocorticoid receptor modulator miricorilant. Liver fat reductions ranged from 38.5% to 73.8% (magnetic resonance imaging measurements in 4 of 5 patients receiving miricorilant, measured between 16-64 days after cessation of miricorilant administration). A further effect of miricorilant was an increase in liver alanine amino transferase (ALT) and aspartate amino transferase (AST).Type: ApplicationFiled: November 3, 2023Publication date: March 7, 2024Applicant: Corcept Therapeutics IncorporatedInventors: Ada Lee, Andreas Grauer, Joseph Belanoff
-
Patent number: 11903945Abstract: Methods of Treating Antipsychotic-Induced Weight Gain with Miricorilant Methods and compositions for treating a subject at risk of, or suffering from antipsychotic-induced weight gain are disclosed. The methods include administration of a cyclohexyl pyrimidine glucocorticoid receptor modulator (GRM) such as miricorilant (CORT118335) to a patient receiving, or who has received, or who is expected to receive, an antipsychotic drug such as olanzapine, risperidone, clozapine, or other weight-inducing antipsychotic medication. The GRM (e.g., miricorilant) may be orally administered. Administration of such a GRM along with antipsychotic medication may reduce the amount of weight, or reduce the rate of weight gain, or prevent weight gain, otherwise due to antipsychotic medication alone. The methods may reverse weight gain in a patient previously administered antipsychotic medication.Type: GrantFiled: December 11, 2020Date of Patent: February 20, 2024Assignee: Corcept Therapeutics IncorporatedInventors: Ada Lee, Joseph Belanoff, Hazel Hunt
-
Publication number: 20230358768Abstract: Methods for treating and differential diagnosis between ACTH-Dependent and ACTH-Independent Cushing's syndrome are disclosed, in which a glucocorticoid receptor antagonist (GRA) is administered to a Cushing's syndrome patient with a basal ACTH level less than about 25 pg/mL. If i) the patients blood ACTH and ii) the patients blood cortisol, or adrenal hormone, or adrenal pre-hormone levels rise, or if the ACTH:cortisol ratio increases, then ACTH-Dependent Cushing's syndrome is diagnosed. If those levels do not rise, or if the ACTH:cortisol ratio decreases, then ACTH-Independent Cushing's syndrome is diagnosed. In some instances, the patient is recovering from surgery to remove an ACTH secreting tumor, and the method described herein is used to determine if the tumor resection was successful or complete.Type: ApplicationFiled: December 18, 2020Publication date: November 9, 2023Applicant: Corcept Therapeutics IncorporatedInventors: Andreas G. Moraitis, Joseph Belanoff
-
Publication number: 20220370446Abstract: Applicant discloses methods and compositions for reducing liver fat and for treating fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH) and nonalcoholic cirrhosis; alcohol related fatty liver diseases including, alcohol fatty liver disease (AFL), alcoholic steatohepatitis (ASH), and alcoholic cirrhosis; and liver fibrosis). Significant liver fat reductions were obtained in human patients after only between 30 to 44 days of administration of 600 mg/day or 900 mg/day of the cyclohexyl pyrimidine glucocorticoid receptor modulator miricorilant. Liver fat reductions ranged from 38.5% to 73.8% (magnetic resonance imaging measurements in 4 of 5 patients receiving miricorilant, measured between 16-64 days after cessation of miricorilant administration). A further effect of miricorilant was an increase in liver alanine amino transferase (ALT) and aspartate amino transferase (AST).Type: ApplicationFiled: May 4, 2022Publication date: November 24, 2022Applicant: Corcept Therapeutics IncorporatedInventors: Ada Lee, Andreas Grauer, Joseph Belanoff
-
Patent number: 11173165Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.Type: GrantFiled: May 5, 2020Date of Patent: November 16, 2021Assignee: Corcept Therapeutics, Inc.Inventors: Joseph Belanoff, Coleman Gross
-
Patent number: 11103514Abstract: The present invention resides in the discovery that glucocorticoid receptor antagonists are effective for treating muscular dystrophy including type 1 or type 2 myotonic dystrophy. Treatment methods and kits are provided.Type: GrantFiled: May 26, 2011Date of Patent: August 31, 2021Assignee: Corcept Therapeutics, Inc.Inventor: Joseph Belanoff
-
Publication number: 20210177848Abstract: Methods of Treating Antipsychotic-Induced Weight Gain with Miricorilant Methods and compositions for treating a subject at risk of, or suffering from antipsychotic-induced weight gain are disclosed. The methods include administration of a cyclohexyl pyrimidine glucocorticoid receptor modulator (GRM) such as miricorilant (CORT118335) to a patient receiving, or who has received, or who is expected to receive, an antipsychotic drug such as olanzapine, risperidone, clozapine, or other weight-inducing antipsychotic medication. The GRM (e.g., miricorilant) may be orally administered. Administration of such a GRM along with antipsychotic medication may reduce the amount of weight, or reduce the rate of weight gain, or prevent weight gain, otherwise due to antipsychotic medication alone. The methods may reverse weight gain in a patient previously administered antipsychotic medication.Type: ApplicationFiled: December 11, 2020Publication date: June 17, 2021Inventors: Ada Lee, Joseph Belanoff, Hazel Hunt
-
Publication number: 20200261471Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.Type: ApplicationFiled: May 5, 2020Publication date: August 20, 2020Inventors: Joseph Belanoff, Coleman Gross
-
Patent number: 10660904Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.Type: GrantFiled: December 13, 2018Date of Patent: May 26, 2020Assignee: Corcept Therapeutics, Inc.Inventors: Joseph Belanoff, Coleman Gross
-
Publication number: 20190117671Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.Type: ApplicationFiled: December 13, 2018Publication date: April 25, 2019Inventors: Joseph Belanoff, Coleman Gross
-
Patent number: 10166243Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.Type: GrantFiled: September 28, 2018Date of Patent: January 1, 2019Assignee: Corcept Therapeutics, Inc.Inventors: Joseph Belanoff, Coleman Gross
-
Patent number: 10166242Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.Type: GrantFiled: March 13, 2018Date of Patent: January 1, 2019Assignee: Corcept Therapeutics, Inc.Inventors: Joseph Belanoff, Coleman Gross
-
Publication number: 20180200265Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.Type: ApplicationFiled: March 13, 2018Publication date: July 19, 2018Inventors: Joseph Belanoff, Coleman Gross
-
Patent number: 9943526Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.Type: GrantFiled: April 20, 2016Date of Patent: April 17, 2018Assignee: Corcept Therapeutics, Inc.Inventors: Joseph Belanoff, Coleman Gross
-
Publication number: 20160310507Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.Type: ApplicationFiled: April 20, 2016Publication date: October 27, 2016Inventors: Joseph Belanoff, Coleman Gross
-
Publication number: 20110294771Abstract: The present invention resides in the discovery that glucocorticoid receptor antagonists are effective for treating muscular dystrophy including type 1 or type 2 myotonic dystrophy. Treatment methods and kits are provided.Type: ApplicationFiled: May 26, 2011Publication date: December 1, 2011Applicant: Corcept Therapeutics, Inc.Inventor: Joseph Belanoff
-
Publication number: 20110166115Abstract: The invention generally pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptor can be used in methods for treating patients diagnosed with Amyotrophic Lateral Sclerosis (ALS).Type: ApplicationFiled: June 30, 2009Publication date: July 7, 2011Applicant: Corcept Therapeutics, Inc.Inventor: Joseph Belanoff
-
Publication number: 20100179115Abstract: The invention pertains to the discovery that type II glucocorticoid receptor antagonists can be used in methods for reversing or inhibiting the symptoms of depression in patients receiving interleukin-2 treatment.Type: ApplicationFiled: May 2, 2007Publication date: July 15, 2010Applicant: Corcept Therapeutics, Inc.Inventor: Joseph Belanoff
-
Publication number: 20060194713Abstract: This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for treating delirium. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods.Type: ApplicationFiled: May 12, 2006Publication date: August 31, 2006Applicant: Corcept Therapeutics, Inc.Inventor: Joseph Belanoff